BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2025-524741-28-00
- Record updated
- 2026. június 5.
- Original description
To evaluate the feasibility and safety of gradual interval prolonging of biologics during ~1 year in patients with severe asthmaRead full original descriptionShow less
To evaluate the feasibility and safety of gradual interval prolonging of biologics during ~1 year in patients with severe asthma
Inclusion: Receiving biological treatment (mepolizumab, reslizumab, benralizumab, dupilumab, or tezepelumab) for more than 12 months; ≥18 years of age; 0 or 1 exacerbation in the past 12 months; Baseline ACQ < 2.0; Blood eosinophil count ≤0.3 +10^9/L for anti-IL-5(R)/Tezepelumab, ≤1.5 +10^9/L for Dupilumab.
Exclusion: Uncontrolled asthma (>1 exacerbation in the past 12 months or ACQ > 2.0); Pregnancy; Intention to become pregnant within the next 12 months; Biologic administration intervals already prolonged beyond the approved regimen according to the SmPC at the patient’s request; Inability to understand and communicate in Dutch or English, both spoken and written.